<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111471</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2801</org_study_id>
    <nct_id>NCT04111471</nct_id>
  </id_info>
  <brief_title>The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients</brief_title>
  <official_title>The Use of Inulin to Prevent Dysbiosis in Pediatric Hematopoietic Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children enrolled in the study will receive either the prebiotic inulin or a placebo for 21
      days during the study period. They will start taking the product seven days before transplant
      starts until 14 days after transplant. Stool will be collected twice weekly until thirty days
      after transplant or discharge, whichever occurs first. Stool samples will be sampled for
      metagenomic sequencing to identify the diversity of bacteria within the stool. They will also
      be analyzed for amount of short-chain fatty acid content (a breakdown product of inulin) as
      well as for presence of genes that confer antibiotic resistance. From 30 days after
      transplant until 100 days after transplant, two stool samples will be collected at regularly
      scheduled follow up appointments (near day 60 and day 100). No product (inulin or placebo)
      will be given during this time frame. The study period ends 100 days after transplant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Qualified patients that are admitted to Lurie Children's Hospital and agree to participate will either be randomized to receive the placebo or prebiotic, inulin. Randomization will occur 1:1</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants will be randomized by an independent statistician based on patient enrollment number (LCH 001- LCH 040). Randomization will be 1:1. The statistician will randomly assort LCH 001-020 into Inulin/Placebo and LCH 021- LCH 040 into Inulin/placebo. This will ensure that an equal number of enrolled participants will be in each arm at 20 patients, and then again at anticipated full 40 patients</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in alpha and beta bacterial diversity measures in stool</measure>
    <time_frame>Change of baseline alpha and beta bacterial diversity at 100 days after transplant</time_frame>
    <description>Compare the effect of oral inulin vs. placebo on alpha and beta bacterial diversity in the stool of children undergoing hematopoietic stem cell transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Short Chain Fatty Acid (SCFA) levels in stool</measure>
    <time_frame>Change in baseline SCFA levels in stool at 100 days after transplant</time_frame>
    <description>Compare the effect of oral inulin vs. placebo on SCFA levels in the stool of children undergoing hematopoietic stem cell transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial Resistance genes in stool</measure>
    <time_frame>Measured at enrollment, on the day of transplant, 30 days after transplant, and near 100 days after transplant</time_frame>
    <description>Determine the impact of inulin intake vs. placebo on the prevalence of genes associated with antibiotic resistance of children undergoing hematopoietic stem cell transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients will receive 5.6 g of placebo product (maltodextrin) daily for a total of 21 days (7 days before and until 2 weeks after transplant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic (Inulin) Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients will receive 10 g of inulin product daily for a total of 21 days (7 days before and until 2 weeks after transplant)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prebiotics</intervention_name>
    <description>Enrolled patients will receive 10 grams of inulin daily for 21 days</description>
    <arm_group_label>Prebiotic (Inulin) Arm</arm_group_label>
    <other_name>inulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>Maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 2-18 years

          2. Allogeneic Stem Cell transplant

          3. Myeloablative therapy

          4. Inpatient at Lurie Children's Hospital

        Exclusion Criteria:

          1. Previous Hematopoietic Stem Cell Transplant

          2. Autologous Stem Cell Transplant

          3. Reduced Intensity Conditioning used for transplant

          4. History of ulcerative colitis, Crohn's disease, irritable bowel syndrome, celiac
             disease

          5. History of Type 1 or Type 2 Diabetes Mellitus

          6. Previous abdominal surgery necessitating the use of an ostomy

          7. G-tube dependence

          8. Nasal gastric/oral gastric tube dependence prior to starting the conditioning process

          9. Graft vs host disease prior to enrollment at any site

         10. Children under 2 years of age - literature shows that the microbiome is still
             developing in children under two years of age, and this development may skew results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander M Newman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lurie Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander M Newman, MD</last_name>
    <phone>3122274080</phone>
    <email>anewman@luriechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mehreen Arshad, MD</last_name>
    <phone>3122274080</phone>
    <email>MArshad@luriechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Alexander Newman</investigator_full_name>
    <investigator_title>Fellow of Pediatric Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Prebiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

